Amoproxan

Summary

Amoproxan (CHEMBL2104537) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 425.5 Da · C22H35NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104537
Name	Amoproxan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	31473
Molecular formula	C22H35NO7
Molecular weight	425.5
InChIKey	YOKPRDAUBGOISU-UHFFFAOYSA-N

SMILES: CC(C)CCOCC(CN1CCOCC1)OC(=O)C2=CC(=C(C(=C2)OC)OC)OC

IUPAC name: [1-(3-methylbutoxy)-3-morpholin-4-ylpropan-2-yl] 3,4,5-trimethoxybenzoate

Also known as: Amoproxan, Amoproxano, CERM 730, CERM-730, SID144206871, AMOPROXAN

Patent coverage: 117 distinct patent families (473 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).